Financial Express (Holdings) Limited (“we”, “our”, “us” and derivatives) are committed to protecting and respecting your privacy. This Privacy Policy, together with our Terms of Use, sets out the basis on which any personal data that we collect from you, or that you provide to us, will be processed by us relating to your use of any of the below websites (“sites”).


For the purposes of the Data Protection Act 1998, the data controller is Trustnet Limited of 2nd Floor, Golden House, 30 Great Pulteney Street, London, W1F 9NN. Our nominated representative for the purpose of this Act is Kirsty Witter.


We collect information about you when you register with us or use any of our websites / services. Part of the registration process may include entering personal details & details of your investments.

We may collect information about your computer, including where available your operating system, browser version, domain name and IP address and details of the website that you came from, in order to improve this site.

You confirm that all information you supply is accurate.


In order to provide personalised services to and analyse site traffic, we may use a cookie file which is stored on your browser or the hard drive of your computer. Some of the cookies we use are essential for the sites to operate and may be used to deliver you different content, depending on the type of investor you are.

You can block cookies by activating the setting on your browser which allows you to refuse the setting of all or some cookies. However, if you use your browser settings to block all cookies (including essential cookies) you may not be able to access all or part of our sites. Unless you have adjusted your browser setting so that it will refuse cookies, our system will issue cookies as soon as you visit our sites.


We store and use information you provide as follows:

  • to present content effectively;
  • to provide you with information, products or services that you request from us or which may interest you, tailored to your specific interests, where you have consented to be contacted for such purposes;
  • to carry out our obligations arising from any contracts between you and us;
  • to enable you to participate in interactive features of our service, when you choose to do so;
  • to notify you about changes to our service;
  • to improve our content by tracking group information that describes the habits, usage, patterns and demographics of our customers.

We may also send you emails to provide information and keep you up to date with developments on our sites. It is our policy to have instructions on how to unsubscribe so that you will not receive any future e-mails. You can change your e-mail address at any time.

In order to provide support on the usage of our tools, our support team need access to all information provided in relation to the tool.

We will not disclose your name, email address or postal address or any data that could identify you to any third party without first receiving your permission.

However, you agree that we may disclose to any regulatory authority to which we are subject and to any investment exchange on which we may deal or to its related clearing house (or to investigators, inspectors or agents appointed by them), or to any person empowered to require such information by or under any legal enactment, any information they may request or require relating to you, or if relevant, any of your clients.

You agree that we may pass on information obtained under Money Laundering legislation as we consider necessary to comply with reporting requirements under such legislation.


We want to ensure that the personal information we hold about you is accurate and up to date. You may ask us to correct or remove information that is inaccurate.

You have the right under data protection legislation to access information held about you. If you wish to receive a copy of any personal information we hold, please write to us at 3rd Floor, Hollywood House, Church Street East, Woking, GU21 6HJ. Any access request may be subject to a fee of £10 to meet our costs in providing you with details of the information we hold about you.


The data that we collect from you may be transferred to, and stored at, a destination outside the European Economic Area (“EEA”). It may be processed by staff operating outside the EEA who work for us or for one of our suppliers. Such staff may be engaged in, amongst other things, the provision of support services. By submitting your personal data, you agree to this transfer, storing and processing. We will take all steps reasonably necessary, including the use of encryption, to ensure that your data is treated securely and in accordance with this privacy policy.

Unfortunately, the transmission of information via the internet is not completely secure. Although we will do our best to protect your personal data, we cannot guarantee the security of your data transmitted to our sites; any transmission is at your own risk. You will not hold us responsible for any breach of security unless we have been negligent or in wilful default.


Any changes we make to our privacy policy in the future will be posted on this page and, where appropriate, notified to you by e-mail.


Our sites contain links to other websites. If you follow a link to any of these websites, please note that these websites have their own privacy policies and that we do not accept any responsibility or liability for these policies. Please check these policies before you submit any personal data to these websites.


If you want more information or have any questions or comments relating to our privacy policy please email [email protected] in the first instance.

 Information  X 
Enter a valid email address

Xenetic Biosciences (XEN)

  Print      Mail a friend

Tuesday 29 November, 2011

Xenetic Biosciences

Completion of Subscription Agreement

RNS Number : 9227S
Xenetic Biosciences PLC
29 November 2011


Xenetic Biosciences PLC

('Xenetic Bio' or the 'Company')


First Closing Update

Completion of Subscription Agreement


£12.18 million Gross Proceeds at premium of 69.2 %


Xenetic Bio (AIM: XEN.L), the bio-pharmaceutical company specialising in the development of high-value differentiated biologic drugs and vaccines, announces completion of the Subscription Agreement entered into as part of the Proposals set out in the Shareholder Circular of 4 August 2011 (the "Circular"), and as approved by shareholders at the Company's General Meeting held on 2 September 2011. Defined terms in this announcement shall have the meanings given to them in the Circular unless the context requires otherwise. 


Pursuant to the Subscription Agreement, SynBio LLC has subscribed for 110,800,000 New Ordinary Shares (the "Subscription Shares") in the Company at 11p per New Ordinary Share, representing a premium of 69.2% to the mid market closing price of a Xenetic Share at close of business on 28 November 2011, thereby raising £12.188 million before expenses. Application has been made to AIM for admission of the Subscription Shares and it is expected that admission will take place on 2 December 2011.


As a result of the issue of the Subscription Shares, the Issued Share Capital of the Company is 288,232,255 Ordinary Shares. SynBio LLC is now the beneficial owner of an aggregate of 144,800,000 Ordinary Shares, representing 50.24% of the Issued Share Capital of the Company as enlarged by the issue of the Subscription Shares.


The Company expects that completion of the acquisition of SymbioTec will occur within the timeframe previously announced, namely by no later than 15 December 2011.


With respect to the proposed Open Offer, the Company will monitor near term market conditions prevailing after completion of First Close (that is, after completion of the acquisition of SymbioTec), particularly as respects the Ordinary Share price, to determine whether the Open Offer should be pursued.


Further announcements will be made in due course.


Commenting on Completion of the Subscription Agreement, M. Scott Maguire, CEO of the Company, said:


"The Company now has the capital to accelerate its drug development pipeline and, in our view, significantly enhance shareholder value. Our primary focus will be on the positive human clinical data that is being generated by our partnerships in Russia and India, thereby providing comfort on the drug candidates' potential for success.


"Our de-risked approach to biotech development is exemplified through the 12 novel drug candidates under the Russian and Indian human proof of concept initiatives; this, combined with the potentially large number of additional new candidates able to be developed utilising our proprietary platform technologies, is expected to yield significant shareholder value going forward. We look forward to the early initiation of clinical trial development in Europe and the USA of the currently most promising candidates."



Xenetic Biosciences plc

+44 (0)20 7389 5015

M. Scott Maguire, Chief Executive Officer

Singer Capital Markets (NOMAD & Broker)

+44 (0)20 3205 7500

Claes Spång

Walbrook PR

Paul McManus

+44 (0)20 7933 8780

[email protected]

Paul McManus

[email protected]

Paul Cornelius

[email protected]


This information is provided by RNS
The company news service from the London Stock Exchange

a d v e r t i s e m e n t